UroFusion-X: Integrated Deep Learning for Urological Cancer Diagnosis and Prognosis

Overview

UroFusion-X is a novel multimodal deep learning framework that integrates imaging, pathology, omics, and laboratory data to improve diagnosis, molecular subtyping, and prognosis prediction in urological cancers. It demonstrates superior accuracy, robustness to missing data, and enhanced clinical utility compared to unimodal and simple fusion approaches.

Background

Urological malignancies such as bladder cancer, renal cell carcinoma, and prostate cancer require comprehensive diagnostic and prognostic evaluation using multiple clinical modalities including radiological imaging, histopathology, molecular profiling, and laboratory tests. While deep learning has advanced single-modality analysis, unimodal approaches fail to capture complementary tumor biology signals across data types, limiting clinical generalizability. Multimodal fusion methods have shown promise but face challenges including underutilization of cross-modal dependencies, missing data in real-world settings, and limited interpretability. Addressing these gaps is critical for precision oncology in urology.

Data Highlights

Key Findings

• UroFusion-X integrates 3D Transformer imaging encoders, MIL pathology encoders, graph neural networks for omics, and TabTransformer for clinical data with a cross-modal co-attention fusion module.
• The framework employs a gated product-of-experts mechanism enabling adaptive weighting and robustness to missing modalities, retaining ≥90% of full-modality performance.
• Anatomy–pathology consistency constraints align radiological regions of interest with pathology attention maps, enhancing interpretability and trust.
• Patient-level contrastive learning improves cross-modal alignment and out-of-distribution generalization across multi-institutional cohorts.
• Time-to-event survival modeling via DeepSurv and DeepHit provides individualized risk estimation and survival distributions.
• UroFusion-X outperforms strong unimodal and simple fusion baselines in diagnostic, subtyping, and prognostic tasks, with higher net clinical benefit demonstrated by decision curve analysis.

Clinical Implications

UroFusion-X offers a clinically robust tool that can improve diagnostic accuracy and prognostic stratification in urological cancers by leveraging complementary multimodal data. Its resilience to missing data and enhanced interpretability support real-world deployment across diverse clinical settings, potentially reducing unnecessary testing and improving personalized patient management.

Conclusion

By unifying heterogeneous clinical data with advanced fusion and interpretability techniques, UroFusion-X advances precision oncology for urological malignancies, demonstrating strong performance, robustness, and clinical utility. This framework paves the way for more consistent and informed decision-making in urological cancer care.

References

1. Wang et al. 2023 -- Multimodal Deep Learning in Oncology
2. Smith et al. 2022 -- Cross-Modal Fusion for Cancer Diagnosis
3. Lee et al. 2021 -- Interpretability in Medical AI
4. Johnson et al. 2020 -- DeepSurv and DeepHit Survival Models
5. Brown et al. 2019 -- Product-of-Experts Fusion Mechanisms